- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02604953
Comparing SD-tVEP and PERG Tests Between Patients With Glaucoma, Patients With High Eye Pressure and "Normal" Patients
1-Year Prospective Study: SD-tVEP and PERG for Early Detection of Retinal Ganglion Cell Dysfunction in Ocular Hypertension Patients
Study Overview
Status
Conditions
Detailed Description
Glaucoma is the most common cause of irreversible blindness worldwide. It is characterized by the progressive loss of retinal ganglion cells (RGCs) and a corresponding loss of vision. Elevated intraocular pressure (IOP) is an important risk factor for glaucoma, but its role in the diagnosis of glaucoma is unclear. Although IOP-lowering therapy delays the onset of glaucoma in some patients with ocular hypertension, even without therapy, 90% of patients will not develop glaucoma over a 5-year period.
Visual evoked potentials (VEPs) are able to detect the disruption of electrical signals at any point along the visual pathway, from the RGCs to the primary visual cortex. As an objective measure of visual function, the VEP may have an advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
There is a growing body of evidence that SD-tVEP can objectively identify early visual dysfunction due to glaucoma.
Aim 1: Compare the results of the baseline SD-tVEP and PERG vision testing in patients with ocular hypertension to a cohort of 30 healthy subjects and a cohort of 30 patients with glaucoma (of varying severity) to determine its ability to detect visual dysfunction in ocular hypertensive subjects.
Aim 2: Conduct SD-tVEP and PERG testing system in 30 patients with ocular hypertension before and after IOP reduction with topical medication and compare the results of the SD-tVEP and PERG before and after treatment in each patient, to determine its ability to detect reversible RGC dysfunction.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Inclusion Criteria for ocular hypertension patients (Group A):
- Patients diagnosed with ocular hypertension as per the ICD-9 code for ocular hypertension (365.04)
- Age between 21 - 80 years
- IOP more than 21 mm hg in both the eyes.
- Open angles on Gonioscopy
- At least 2 normal and reliable visual fields (Humphrey MD >-2 or Octopus MD ≤0.8; fixation losses, false-positive rate, and false-negative rate each < 33%)
- Normal optic disks, without any of the following signs: rim notches, peripapillary splinter hemorrhages, or C/D asymmetry >0.2 between the two eyes
- BCVA ≥ 20/40, Clear media, Pupil diameter > 3 mm and symmetric
- Spherical refraction within + 5.0 D and cylinder correction within + 3.0 D.
Inclusion Criteria for glaucoma patients (Group B):
- Patients diagnosed with mild, moderate or severe open angle glaucoma as per the (365.xx)
- Age between 21 - 80 years.
- Patients who attend regular follow-up.
Inclusion Criteria for normal subjects (Group C):
- Individuals with no ocular hypertension or any type of glaucoma.
- Available to participate in the study during the required time frame.
- Age 21-80 years.
Exclusion Criteria:
- Incisional eye surgery within the past three months.
- Neurological or musculoskeletal problems that would influence performance on activities of daily living.
- Laser therapy within the previous month.
- Any cause for visual reduction (greater than 20/40 VA) other than glaucoma.
- Any medical condition which in the investigator's opinion would preclude the subject from providing reliable and valid data.
- History of hypersensitivity to Bimatoprost and Brimonidine, or currently taking an MAO inhibitor
- Currently taking any IOP lowering therapies.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Ocular Hypertension patients
Ocular hypertension patients are recruited from the Wills Eye Hospital Glaucoma Service.
Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
|
Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex.
As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
Other Names:
Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC).
In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
Other Names:
|
Healthy Controls
Healthy adults are recruited from staff, family and friends of Wills Eye Hospital Glaucoma Research Center.
Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
|
Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex.
As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
Other Names:
Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC).
In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
Other Names:
|
Glaucoma patients
Glaucoma patients are recruited from the Wills Eye Hospital Glaucoma Service.
Short Duration Transient Visual Evoked Potential (SD- tVEP) and Pattern electroretinogram (PERG) testing will be conducted.
|
Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex.
As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
Other Names:
Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC).
In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short Duration Transient Visual Evoked Potential (SD- tVEP)
Time Frame: 1 day
|
Short Duration Transient Visual Evoked Potential (VEP) to objectively measure the functional responses of the entire visual pathway from the anterior segment of the eye to the visual cortex.
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anand Mantravadi, MD, Wills Eye Hospital
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 13-358
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma
-
Centre hospitalier de l'Université de Montréal...CompletedGlaucoma | Glaucoma, Open-Angle | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma and Ocular Hypertension | Glaucoma, Uncompensated | Glaucoma SecondaryCanada
-
Pro Top & Mediking Company LimitedCompletedOpen Angle Glaucoma | Neovascular Glaucoma | Angle Closure Glaucoma | Uveitis Glaucoma | Young Age Glaucoma | High Risk PatientEstonia
-
Imperial College Healthcare NHS TrustIRIDEX CorporationNot yet recruitingGlaucoma | Glaucoma, Open-Angle | Glaucoma, Angle-Closure | Glaucoma, Neovascular | Glaucoma Eye | Glaucoma Secondary | Glaucoma Traumatic | Glaucoma Uveitic
-
Wills EyeIOP OphthalmicsTerminatedPrimary Open Angle Glaucoma | Neovascular Glaucoma | Uveitic Glaucoma | Pseudoexfoliation Glaucoma | Primary Angle Closure Glaucoma | Pigmentary Glaucoma | Traumatic GlaucomaUnited States
-
Sanoculis LtdCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaIsrael
-
Bausch & Lomb IncorporatedNicOx Inc.CompletedPrimary Open Angle Glaucoma | Ocular Hypertension | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
Sensimed AGCompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaFrance
-
Wills EyeOptovueCompletedPrimary Open-angle Glaucoma | Normal Tension Glaucoma | Glaucoma; DrugsUnited States
-
Ivantis, Inc.CompletedPrimary Open Angle Glaucoma | Pigmentary Glaucoma | Pseudoexfoliative GlaucomaUnited States
-
University of California, San FranciscoUniversity of Colorado, Denver; University of Maryland; Zhongshan Ophthalmic... and other collaboratorsCompletedPrimary Open Angle Glaucoma | Glaucoma | Neovascular Glaucoma | Secondary GlaucomaUnited States, China, India, Mexico
Clinical Trials on Short Duration Transient Visual Evoked Potential (SDtVEP)
-
Assiut UniversityNot yet recruitingRelapsing Remitting Multiple Sclerosis
-
Benha UniversityRecruitingVision Disorders | Visual Impairment | Retinal DiseaseEgypt
-
University of Wisconsin, MadisonMeriter FoundationRecruitingHypoxic-Ischemic Encephalopathy | Neonatal Encephalopathy | EncephalopathyUnited States
-
Medical University of BialystokUniversity of BialystokRecruitingOptic Neuritis | Ischemic Optic Neuropathy | Traumatic Optic Neuropathy | Toxic Optic Neuropathy | Compressive Optic Neuropathy | Hereditary Optic NeuropathiesPoland
-
Wills EyeCompletedHow Accurately Does the Diopsys Visual Evoked Potential (VEP) Vision Testing System Detect Glaucoma?Glaucoma DiagnosisUnited States
-
Brugmann University HospitalRecruitingMultiple SclerosisBelgium
-
Wills EyeCompleted
-
Mansoura University HospitalUnknownMultiple Sclerosis | Sexual DysfunctionEgypt